|
Balance Sheet Cash Flow Statement 1110 Spring St. Silver Spring, MD 20910 MD Tel. 301-608-9292 Fax 301-608-9291 |
Type: Public
On the web:
http://www.unither.com
Employees:
360
Employee growth: 12.5%
United Therapeutics hopes its products will be in vein. Its intravenous drug Remodulin treats pulmonary hypertension, which affects the blood vessels between the heart and lungs; the firm is also investigating Remodulin to improve liver transplant outcomes. Other products in the biotech's pipeline aim to treat cardiovascular disease, as well as various cancers and infectious diseases. In addition to its drug development activities, United Therapeutics' Medicomp unit provides cardiac monitoring services over the phone and Internet using its CardioPAL event monitors, which detect heart arrhythmias and ischemic heart disease.
Key numbers for fiscal year ending December, 2008:
Sales: $281.5M
One year growth: 33.4%
Net income: ($42.8)M
Officers:
Chairman and CEO: Martine A. Rothblatt
President, COO, and Director: Roger Jeffs
CFO and Treasurer: John M. Ferrari
Competitors:
Actelion
Bayer Schering Pharma
Gilead Sciences
